Neonatal gene transfer using lentiviral vector for murine Pompe disease: long-term expression and glycogen reduction
- 24 December 2009
- journal article
- research article
- Published by Springer Science and Business Media LLC in Gene Therapy
- Vol. 17 (4), 521-530
- https://doi.org/10.1038/gt.2009.160
Abstract
Pompe disease results from the deficiency of the lysosomal enzyme acid alpha-glucosidase (GAA), leading to accumulated glycogen in the heart and the skeletal muscles, which causes cardiomyopathy and muscle weakness. In this study, we tested the feasibility of gene therapy for Pompe disease using a lentivirus vector (LV). Newborn GAA knockout mice were treated with intravenous injection of LV encoding human GAA (hGAA) through the facial superficial temporal vein. The transgene expression in the tissues was analyzed up to 24 weeks after treatment. Our results showed that the recombinant LV was efficient not only in increasing the GAA activity in tissues but also in decreasing their glycogen content. The examination of histological sections showed clearence of the glycogen storage in skeletal and cardiac muscles 16 and 24 weeks after a single vector injection. Levels of expressed hGAA could be detected in serum of treated animals until 24 weeks. No significant immune reaction to transgene was detected in most treated animals. Therefore, we show that LV-mediated delivery system was effective in correcting the biochemical abnormalities and that this gene transfer system might be suitable for further studies on delivering GAA to Pompe disease mouse models.Keywords
This publication has 51 references indexed in Scilit:
- Impaired clearance of accumulated lysosomal glycogen in advanced Pompe disease despite high‐level vector‐mediated transgene expressionThe Journal of Gene Medicine, 2009
- Correction of Multiple Striated Muscles in Murine Pompe Disease Through Adeno-associated Virus–mediated Gene TherapyMolecular Therapy, 2008
- Immune tolerance induction to enzyme-replacement therapy by co-administration of short-term, low-dose methotrexate in a murine Pompe disease modelClinical and Experimental Immunology, 2008
- Enhanced Response to Enzyme Replacement Therapy in Pompe Disease after the Induction of Immune ToleranceAmerican Journal of Human Genetics, 2007
- Autophagy and Mistargeting of Therapeutic Enzyme in Skeletal Muscle in Pompe DiseaseMolecular Therapy, 2006
- Gene transfer in humans using a conditionally replicating lentiviral vectorProceedings of the National Academy of Sciences, 2006
- Limited Transgene Immune Response and Long-Term Expression of Humanα-L-Iduronidase in Young Adult Mice with Mucopolysaccharidosis Type I by Liver-Directed Gene TherapyHuman Gene Therapy, 2006
- Chinese hamster ovary cell-derived recombinant human acid α-glucosidase in infantile-onset Pompe diseaseThe Journal of Pediatrics, 2006
- Pompe disease in infants and childrenThe Journal of Pediatrics, 2004
- LMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1Science, 2003